After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Ryan Cross

Senior Science Correspondent

A secretive biotech startup developing a new form of gene editing is starting to give curious scientists a peek at its pipeline — without fully divulging …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Af­ter rais­ing half a bil­lion dol­lars, a se­cre­tive biotech gives an ear­ly look at its gene edit­ing pipeline

Senior Science Correspondent

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline